Finance, Grants, Deals

Novo A/S, the financing entity that is at the apex of Denmark’s pharmaceutical industry, has acquired all the share capital of Xellia Pharmaceuticals AS of Norway for about $700 million. One of the sellers was Britain’s 3i Group Plc.

Location

SuppreMol GmbH, which specialises in autoimmune diseases, has raised €9.5 million as the second part of a €16 million series D financing for the Phase 2 development of its lead autoimmune drug candidate.

Location

Elan Corporation Plc has announced a further restructuring and a share repurchase plan in a bid to win over shareholders who are being wooed by the US investment group Royalty Pharma in an unsolicited takeover bid.

Location

Atlas Ventures of the US has entered into new partnership agreements with Amgen and Novartis in connection with the closing of its ninth investment fund Atlas IX. The two companies are limited partners of the fund, and will participate in the creation of new  startup companies.

AbbVie Inc (formerly part of Abbott Laboratories) is expanding its collaboration with Galápagos NV of Belgium to take the Galápagos JAK1 inhibitor, GLPG0634, into Crohn’s disease. The molecule is already being investigated for rheumatoid arthritis.

Location

Cardio3 BioSciences SA, which has an autologous cell therapy for patients with chronic heart failure in the clinic, has raised €19 million in a private placement with existing investors to finance the clinical development of its lead product.

Location

Symphogen A/S of Denmark has raised an additional €41 million from private investors towards the development of its portfolio of compounds in oncology which are antibody mixture products addressing multiple targets in a single product.

Location

Oxford BioMedica Plc has signed a contract with Novartis to supply the Swiss company with lentiviral vector material for clinical trials involving a new immunotherapy. The contract is valued at up to £4 million.

Location

In another example of Big Pharma collaboration in the area of diabetes, Merck & Co Inc has announced plans to collaborate with Pfizer in the development and commercialisation of ertugliflozin, a Phase 3-ready diabetes drug in the SGLT2 class.

Location

GlaxoSmithKline Plc has ended a collaboration with Impax Pharmaceuticals on a late-stage Parkinson’s disease drug, citing delays in the drug’s anticipated regulatory review and launch dates in countries where GSK has commercialisation rights.

Location